Regenerative Cardiac Pharmacology
As a part of the Regenerative Pharmacology Unit of the Drug Research Program, our group aims at discovering new ways to treat heart diseases by investigating the molecular mechanisms of cardiac regeneration and thereby identifying new potential drug targets. In particular, we are interested in two cell types: cardiomyocytes, i.e. heart muscle cells, and vascular endothelial cells, and we aim to find ways to promote cardiomyocyte renewal after a myocardial infarction. We are also interested in finding treatments that inhibit pathological cardiac remodelling: hypertrophy (thickening) and fibrosis (stiffening) of the left ventricular wall. We develop, screen and characterise new compounds with potential to enhance the regenerative capacity of the heart or to inhibit cardiac remodelling.
News and Twitter
New publication: Role of PKC isoforms in cardiomyocyte hypertrophy
Our article entitled “Pharmacological protein kinase C modulators reveal a pro-hypertrophic role for novel protein kinase C isoforms in human...
New publication – The potential of targeting PKC for the inhibition of cardiac fibrosis
Our paper entitled “Distinct regulation of cardiac fibroblast proliferation and transdifferentiation by classical and novel protein kinase C...
Cardiovascular diseases are the leading cause of death worldwide. Despite current treatments, the prognosis of heart failure is poor:...